A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This randomized, controlled, phase II clinical study is designed to assess the efficacy of
preemptive treatment with topical steroids in preventing the papulopustular eruption induced
by epidermal growth factor receptor inhibitor (EGFRI) treatment in cancer patients.
Participants will be followed up for 6 weeks of twice daily application of triamcinolone
cream to the face, chest, and back.